Live Breaking News & Updates on Clinical Breast Cancer Research

Stay updated with breaking news from Clinical breast cancer research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Hafez on the Design of the FeDeriCa Trial in HER2+ Early Breast Cancer

Maria Hafez, MD, discusses the design of, and outcomes from, the phase 3 FeDeriCa trial in patients with HER2-positive early breast cancer. ....

Maria Hafez , Sidney Kimmel Medical College , Thomas Jefferson University , Clinical Breast Cancer Research , Federica Trial , Patients With Her2 Positive Early Breast Cancer ,

Post-Surgery Atezolizumab Fails to Provide Benefit in Combination With Chemotherapy for TNBC

Adjuvant atezolizumab did not provide a clinical benefit when added to chemotherapy in patients with triple-negative breast cancer. ....

San Antonio , United States , Heather Mcarthur , Clinical Breast Cancer Research , Ut Southwestern Medical Center , European Breast Cancer Conference , Komen Distinguished Chair , Medical Center , Antonio Breast Cancer Symposium , Alexandra Impassion030 Trial , 14th European Breast Cancer Conference , Atezolizumab Plus Chemotherapy , Triple Negative Breast Cancer ,

MRD Testing Presents Challenges and Opportunities in Breast Cancer Care

Heather McArthur, MD, MPH, discusses the prognostic benefits of circulating tumor DNA and limitations that prevent these results from being predictive. ....

United States , Eli Lilly , Daiichi Sankyo , Genentech Roche , Heather Mcarthur , Department Of Internal Medicine , Syndax Pharmaceuticals , Breast Cancer Program , Clinical Breast Cancer Research , Bristol Myers Squibb , Spectrum Pharmaceuticals , Annual Miami Breast Cancer , Internal Medicine , Komen Distinguished Chair , Comprehensive Cancer Center , Metastatic Success , Disease Recurrence With , Early Stage Breast , Seattle Genetics , International Association ,

Dr McArthur on Neoadjuvant Pembrolizumab Plus Chemotherapy in ER+/HER2– Breast Cancer

Heather Lynn McArthur, MD, MPH, discusses the primary results from the phase 3 KEYNOTE-756 study of neoadjuvant pembrolizumab plus chemotherapy in early-stage, high-risk, estrogen receptor–positive, HER2-negative breast cancer. ....

Heather Lynn Mcarthur , Department Of Internal Medicine , Breast Cancer Program , Clinical Breast Cancer Research , Ut Southwestern Medical Center , Oncology Division , Simmons Cancer Center , Internal Medicine , Medical Center , Komen Distinguished Chair , Ut Southwestern Haroldc Simmons Comprehensive Cancer Center , Onclive Tv , Breast Cancer ,

ESMO 2023: Experts Preview Anticipated Data Spanning Tumor Types

The 2023 ESMO Congress, which is taking place in Madrid, Spain, and will continue to be accessible online via a virtual platform, is gearing up to kick off, and the oncology community is ready to learn more about the latest data across malignancies. ....

United States , Ibiayi Dagogo Jack , Kishor Ganti , Novartis Pluvicto , Pembrolizumab Keytruda , Heather Mcarthur , Daiichi Sankyo , Balazs Halmos , Genentech Alecensa , Heather Wakelee , Jeffreys Weber , Dagogo Jack , Christopherk Glanz , Perlmutter Cancer Center , Bladder Cancer Research , Melanoma Research Program , Department Of Internal Medicine , Division Of Oncology Hematology , Harvard Medical School , Pamela Buffett Cancer Center , Drug Administration , Adventhealth Cancer Institute , Breast Cancer Program At Simmons Center , Department Of Oncology , Ut Southwestern Medical Center , Clinical Research Unit ,